Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
As many in the field have said before, what we really need are antifungals with a truly novel MoA, not minor changes to well-established classes.[1] There is a shortage of new antifungals for invasive disease. Small improvements in PK will hardly move the field forward or excite investors to engage. Our current Continue reading The Antifungal Landscape – 2
It is amazing how modifications to the azole structure have produced ever more potent, ever more useful antifungals. Ketoconazole had limited usability because of its many side effects related to off-target sterol synthesis inhibition, solubility (or lack thereof) and erratic absorption. Solublity was also an issue for itraconazole and posaconazole. Continue reading Cresemba / Isavuconazole: Not Just Another Azole